Applied Therapeutics is a clinical-stage biopharmaceutical company developing a pipeline of product candidates against validated molecular targets in indications of high unmet medical need. AT-007 is a central nervous system penetrant ARI that Co. is developing for the treatment of metabolic diseases, including Galactosemia, a pediatric metabolic disease that affects how the body processes a simple sugar called galactose. AT-001 is an ARI with systemic exposure and peripheral nerve permeability that Co. is developing for the treatment of diabetic cardiomyopathy. AT-003 is an ARI designed to cross through the back of the eye when dosed orally for the treatment of diabetic retinopathy. The APLT average annual return since 2019 is shown above.
The Average Annual Return on the APLT average annual return since 2019 page and across the coverage universe of our site,
is a measure of the annualized return over the past ten years (or specified start date) for a given investment
(up to the end of prior trading session recorded). Arguably, choosing ten years for a measurement
period is on the one hand completely arbitrary, but on the other hand provides a sufficiently long window
to capture long-term trends.
Thus, researching Average Annual Returns is good practice for investors — whether APLT average annual return since 2019 or other benchmarks/peers
— and when doing so it is also important to factor in dividends, because a financial instrument's annualized return is
more than just the change in price if that instrument pays a dividend or coupon. Our website aims to empower investors
by performing the APLT average annual return calculation with any dividends reinvested as applicable (on ex-dates).
|